Advanced Life Sciences Holdings, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel drugs in the areas of infectious disease, oncology, and respiratory disease. Its lead candidate includes Cethromycin, a novel once-a-day oral antibiotic under review by the FDA for the treatment of mild-to-moderate community acquired pneumonia. Cethromycin has also completed Phase III clinical trials for the treatment of respiratory tract infections. The company also has an exclusive worldwide license agreement with Abbott Laboratories for the development and commercialization of Cethromycin. Advanced Life Sciences? products under preclinical studies comprise ALS-357, a compound for the treatment of malignant melanoma; and ALS-886, a novel therapeutic for the treatment of inflammation-related tissue damage consisting of tissue damage associated with acute respiratory distress syndrome. Its products under preclinical studies also include product candidates derived from the company?s natural products-based chemistry platform. Advanced Life Sciences has collaborations and license agreements with Wyeth Pharmaceuticals, University of Illinois at Chicago, Baxter International, National Institute of Allergy and Infectious Diseases, and Defence Science and Technology Laboratory of the United Kingdom. The company was founded in 1999 and is headquartered in Woodridge, Illinois.